Immunology in the clinic review series; focus on cancer: Glycolipids as targets for tumour immunotherapy

Clinical and Experimental Immunology

Volumn 167, Issue 2, 2012, Pages 206-215

  Durrant, L G ^a   Noble, P ^a   Spendlove, I ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cancer vaccine; Glycolipid; Glycosylation; Immunotherapy; Monoclonal antibody

Indexed keywords

CA 19-9 ANTIGEN; CANCER VACCINE; GANGLIOSIDE GD2; GLYCOSPHINGOLIPID; MONOCLONAL ANTIBODY;

BLOOD GROUP LEWIS SYSTEM; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; FUCOSYLATION; GLYCOSYLATION; HUMAN; LIPOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CANCER VACCINES; CERAMIDES; CLINICAL TRIALS AS TOPIC; G(M3) GANGLIOSIDE; GANGLIOSIDES; GLYCOLIPIDS; GLYCOSYLATION; HUMANS; IMMUNOTHERAPY; LEWIS BLOOD-GROUP SYSTEM; MOLECULAR TARGETED THERAPY; NEOPLASMS; TRISACCHARIDES;

EID: 84855803916     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04516.x     Document Type: Review

References (112)

1. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci USA 2002; 99:10231-3.
2. Zhong LT, Manzi A, Skowronski E etal. A monoclonal antibody that induces neuronal apoptosis binds a metastasis marker. Cancer Res 2001; 61:5741-8.
3. Zhang G, Zhang H, Wang Q etal. Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker. Proc Natl Acad Sci USA 2010; 107:732-7.
4. Loo D, Pryer N, Young P etal. The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo. Mol Cancer Ther 2007; 6:856-65.
5. Alvarez-Rueda N, Leprieur S, Clemenceau B etal. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen. Clin Cancer Res 2007; 13:5613s-20s.
6. Hellstrom I, Garrigues HJ, Garrigues U, Hellstrom KE. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res 1990; 50:2183-90.
7. Chou HH, Takematsu H, Diaz S etal. A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci USA 1998; 95:11751-6.
8. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular biology of the cell, 4th edn. New York: Garland Science, 2002.
9. Ichikawa S, Hirabayashi Y. Glucosylceramide synthase and glycosphingolipid synthesis. Trends Cell Biol 1998; 8:198-202.
10. Sprong H, Kruithof B, Leijendekker R, Slot JW, van Meer G, van der Sluijs P. UDP-galactose: ceramide galactosyltransferase is a class I integral membrane protein of the endoplasmic reticulum. J Biol Chem 1998; 273:25880-8.
11. Lannert H, Bunning C, Jeckel D, Wieland FT. Lactosylceramide is synthesized in the lumen of the Golgi apparatus. FEBS Lett 1994; 342:91-6.
12. Won JS, Singh AK, Singh I. Lactosylceramide: a lipid second messenger in neuroinflammatory disease. J Neurochem 2007; 103 (Suppl. 1):180-91.
13. Hettmer S, McCarter R, Ladisch S, Kaucic K. Alterations in neuroblastoma ganglioside synthesis by induction of GD1b synthase by retinoic acid. Br J Cancer 2004; 91:389-97.
14. Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science 2010; 327:46-50.
15. Iwabuchi K, Yamamura S, Prinetti A, Handa K, Hakomori S. GM3-enriched microdomain involved in cell adhesion and signal transduction through carbohydrate-carbohydrate interaction in mouse melanoma B16 cells. J Biol Chem 1998; 273:9130-8.
16. Kojima N, Hakomori S. Cell adhesion, spreading, and motility of GM3-expressing cells based on glycolipid-glycolipid interaction. J Biol Chem 1991; 266:17552-8.
17. Suzuki C, Kojima N. A cholesterol-independent membrane microdomain serves as a functional counter-receptor for E-selectin at the Colo201 cell surface and initiates signalling on E-selectin binding. J Biochem 2007; 142:55-64.
18. Thorne RF, Mhaidat NM, Ralston KJ, Burns GF. Shed gangliosides provide detergent-independent evidence for type-3 glycosynapses. Biochem Biophys Res Commun 2007; 356:306-11.
19. Mitsuzuka K, Handa K, Satoh M, Arai Y, Hakomori S. A specific microdomain ('glycosynapse 3') controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha3beta1 integrin with CD9. J Biol Chem 2005; 280:35545-53.
20. Zheng M, Fang H, Tsuruoka T, Tsuji T, Sasaki T, Hakomori S. Regulatory role of GM3 ganglioside in alpha 5 beta 1 integrin receptor for fibronectin-mediated adhesion of FUA169 cells. J Biol Chem 1993; 268:2217-22.
21. Zheng M, Fang H, Hakomori S. Functional role of N-glycosylation in alpha 5 beta 1 integrin receptor. De-N-glycosylation induces dissociation or altered association of alpha 5 and beta 1 subunits and concomitant loss of fibronectin binding activity. J Biol Chem 1994; 269:12325-31.
22. Ono M, Handa K, Withers DA, Hakomori S. Glycosylation effect on membrane domain (GEM) involved in cell adhesion and motility: a preliminary note on functional alpha3, alpha5-CD82 glycosylation complex in ldlD 14 cells. Biochem Biophys Res Commun 2000; 279:744-50.
23. Hakomori S. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res 1985; 45:2405-14.
24. Reis CA, Osorio H, Silva L, Gomes C, David L. Alterations in glycosylation as biomarkers for cancer detection. J Clin Pathol 2010; 63:322-9.
25. Kawamura YI, Toyota M, Kawashima R etal. DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer. Gastroenterology 2008; 135:142-51e3.
26. Itai S, Nishikata J, Yoneda T etal. Tissue distribution of 2-3 and 2-6 sialyl Lewis A antigens and significance of the ratio of two antigens for the differential diagnosis of malignant and benign disorders of the digestive tract. Cancer 1991; 67:1576-87.
27. Kannagi R. Molecular mechanism for cancer-associated induction of sialyl Lewis X and sialyl Lewis A expression-the Warburg effect revisited. Glycoconj J 2004; 20:353-64.
28. Wei J, Cui L, Liu F etal. E-selectin and sialyl Lewis X expression is associated with lymph node metastasis of invasive micropapillary carcinoma of the breast. Int J Surg Pathol 2010; 18:193-200.
29. St Hill CA, Baharo-Hassan D, Farooqui M. C2-O-sLe glycoproteins are E-selectin ligands that regulate invasion of human colon and hepatic carcinoma cells. PLoS ONE 2011; 6:e16281.
30. Kannagi R, Yin J, Miyazaki K, Izawa M. Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants - Hakomori's concepts revisited. Biochim Biophys Acta 2008; 1780:525-31.
31. Koike T, Kimura N, Miyazaki K etal. Hypoxia induces adhesion molecules on cancer cells: a missing link between Warburg effect and induction of selectin-ligand carbohydrates. Proc Natl Acad Sci USA 2004; 101:8132-7.
32. Ogawa J, Inoue H, Koide S. Glucose-transporter-type-I-gene amplification correlates with sialyl-Lewis-X synthesis and proliferation in lung cancer. Int J Cancer 1997; 74:189-92.
33. Miyoshi E, Moriwaki K, Nakagawa T. Biological function of fucosylation in cancer biology. J Biochem 2008; 143:725-9.
34. Moriwaki K, Miyoshi E. Fucosylation and gastrointestinal cancer. World J Hepatol 2010; 2:151-61.
35. Tsuchida T, Saxton RE, Morton DL, Irie RF. Gangliosides of human melanoma. Cancer 1989; 63:1166-74.
36. Dubois C, Magnani JL, Grunwald GB etal. Monoclonal antibody 18B8, which detects synapse-associated antigens, binds to ganglioside GT3 (II3 (NeuAc)3LacCer). J Biol Chem 1986; 261:3826-30.
37. Hamilton WB, Helling F, Lloyd KO, Livingston PO. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer 1993; 53:566-73.
38. Brodin T, Thurin J, Stromberg N, Karlsson KA, Sjogren HO. Production of oligosaccharide-binding monoclonal antibodies of diverse specificities by immunization with purified tumor-associated glycolipids inserted into liposomes with lipid A. Eur J Immunol 1986; 16:951-6.
39. Yamada N, Chung YS, Takatsuka S etal. Increased sialyl Lewis A expression and fucosyltransferase activity with acquisition of a high metastatic capacity in a colon cancer cell line. Br J Cancer 1997; 76:582-7.
40. Jeschke U, Mylonas I, Shabani N etal. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis. Anticancer Res 2005; 25:1615-22.
41. Charpin C, Bhan AK, Zurawski VR Jr, Scully RE. Carcinoembryonic antigen (CEA) and carbohydrate determinant 19-9 (CA 19-9) localization in 121 primary and metastatic ovarian tumors: an immunohistochemical study with the use of monoclonal antibodies. Int J Gynecol Pathol 1982; 1:231-45.
42. Magnani JL, Nilsson B, Brockhaus M etal. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem 1982; 257:14365-9.
43. Nakagoe T, Sawai T, Tsuji T etal. Circulating sialyl Lewis(x), sialyl Lewis(a), and sialyl Tn antigens in colorectal cancer patients: multivariate analysis of predictive factors for serum antigen levels. J Gastroenterol 2001; 36:166-72.
44. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 1987; 47:1098-104.
45. Wu ZL, Schwartz E, Seeger R, Ladisch S. Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res 1986; 46:440-3.
46. Yoshida S, Kawaguchi H, Sato S, Ueda R, Furukawa K. An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation. Jpn J Cancer Res 2002; 93:816-24.
47. Portoukalian J, Zwingelstein G, Dore JF. Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem 1979; 94:19-23.
48. Distler U, Souady J, Hulsewig M etal. Shiga toxin receptor Gb3Cer/CD77: tumor-association and promising therapeutic target in pancreas and colon cancer. PLoS ONE 2009; 4:e6813.
49. Chang F, Li R, Ladisch S. Shedding of gangliosides by human medulloblastoma cells. Exp Cell Res 1997; 234:341-6.
50. Sa G, Das T, Moon C etal. GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells. Cancer Res 2009; 69:3095-104.
51. Devine PL, Clark BA, Birrell GW etal. The breast tumor-associated epitope defined by monoclonal antibody 3E1·2 is an O-linked mucin carbohydrate containing N-glycolylneuraminic acid. Cancer Res 1991; 51:5826-36.
52. Oliva JP, Valdes Z, Casaco A etal. Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc. Breast Cancer Res Treat 2006; 96:115-21.
53. Higashi H, Sasabe T, Fukui Y, Maru M, Kato S. Detection of gangliosides as N-glycolylneuraminic acid-specific tumor-associated Hanganutziu-Deicher antigen in human retinoblastoma cells. Jpn J Cancer Res 1988; 79:952-6.
54. Bardor M, Nguyen DH, Diaz S, Varki A. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J Biol Chem 2005; 280:4228-37.
55. Gabri MR, Otero LL, Gomez DE, Alonso DF. Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines. J Exp Clin Cancer Res 2009; 28:146-54.
56. de Leon J, Fernandez A, Mesa C, Clavel M, Fernandez LE. Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother 2006; 55:443-50.
57. Buskas T, Thompson P, Boons GJ. Immunotherapy for cancer: synthetic carbohydrate-based vaccines. Chem Commun (Camb) 2009; 36:5335-49.
58. Mond JJ, Vos Q, Lees A, Snapper CM. T cell independent antigens. Curr Opin Immunol 1995; 7:349-54.
59. Tolar P, Hanna J, Krueger PD, Pierce SK. The constant region of the membrane immunoglobulin mediates B cell-receptor clustering and signaling in response to membrane antigens. Immunity 2009; 30:44-55.
60. Cipolla L, Peri F, Airoldi C. Glycoconjugates in cancer therapy. Anticancer Agents Med Chem 2008; 8:92-121.
61. Ragupathi G, Livingston PO, Hood C etal. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 2003; 9:5214-20.
62. Krug LM, Ragupathi G, Hood C etal. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin Cancer Res 2004; 10:6094-100.
63. Livingston PO. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 1995; 145:147-66.
64. Livingston PO, Wong GY, Adluri S etal. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12:1036-44.
65. Kitamura K, Livingston PO, Fortunato SR etal. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. Proc Natl Acad Sci USA 1995; 92:2805-9.
66. Helling F, Zhang S, Shang A etal. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995; 55:2783-8.
67. Slovin SF, Keding SJ, Ragupathi G. Carbohydrate vaccines as immunotherapy for cancer. Immunol Cell Biol 2005; 83:418-28.
68. Eggermont AM, Suciu S, Rutkowski PM etal. EOTRC Melanoma Group, randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: final results of study EORTC 18961. J Clin Oncol 2010; 28:2012-18.
69. Chapman PB, Wu D, Ragupathi G etal. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin Cancer Res 2004; 10:4717-23.
70. Giaccone G, Debruyne C, Felip E etal. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guérin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 2005; 23:6854-64.
71. Hernandez AM, Rodriguez N, Gonzalez JE etal. Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism. J Immunol 2011; 186:3735-44.
72. Fernandez LE, Gabri MR, Guthmann MD etal. NGcGM3 ganglioside: a privileged target for cancer vaccines. Clin Dev Immunol 2010; 2010:814397-405.
73. Fuentes D, Avellanet J, Garcia A etal. Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model. Breast Cancer Res Treat 2010; 120:379-89.
74. Alfonso S, Diaz RM, de la Torre A etal. 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. Cancer Biol Ther 2007; 6:1847-52.
75. Guthmann MD, Castro MA, Cinat G etal. Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J Immunother 2006; 29:215-23.
76. Hernandez AM, Toledo D, Martinez D etal. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol 2008; 181:6625-34.
77. Osorio M, Gracia E, Rodriguez E etal. Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study. Cancer Biol Ther 2008; 7:488-95.
78. Livingston PO, Ritter G, Calves MJ. Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse. Cancer Immunol Immunother 1989; 29:179-84.
79. Estevez F, Carr A, Solorzano L etal. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine 1999; 18:190-7.
80. Guthmann MD, Bitton RJ, Carnero AJ etal. Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity. J Immunother 2004; 27:442-51.
81. Ragupathi G, Damani P, Srivastava G etal. Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine. Cancer Immunol Immunother 2009; 58:1397-405.
82. Sabbatini PJ, Kudryashov V, Ragupathi G etal. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Int J Cancer 2000; 87:79-85.
83. Cox D, Fox L, Tian R etal. Determination of cellular lipids bound to human CD1d molecules. PLoS ONE 2009; 4:e5325.
84. Blanca IR, Bere EW, Young HA, Ortaldo JR. Human B cell activation by autologous NK cells is regulated by CD40-CD40 ligand interaction: role of memory B cells and CD5+ B cells. J Immunol 2001; 167:6132-9.
85. Leadbetter EA, Brigl M, Illarionov P etal. NK T cells provide lipid antigen-specific cognate help for B cells. Proc Natl Acad Sci USA 2008; 105:8339-44.
86. Dullforce P, Sutton DC, Heath AW. Enhancement of T cell-independent immune responses in vivo by CD40 antibodies. Nat Med 1998; 4:88-91.
87. y determinants. Proc Natl Acad Sci USA 1994; 91:12957-61.
88. Tolcher A, Sugarman S, Gelmon K etal. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 1999; 17:478-84.
89. Pai LH, Wittes R, Setser A, Willingham MC, Pastan I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med 1996; 2:350-3.
90. Manimala JC, Roach TA, Li Z, Gildersleeve JC. High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems. Glycobiology 2007; 17:17C-23C.
91. Durrant LG, Harding SJ, Green NH, Buckberry LD, Parsons T. A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis. Cancer Res 2006; 66:5901-9.
92. Sawada R, Sun SM, Wu X etal. Human monoclonal antibodies to sialyl-Lewisa (CA19·9) with potent CDC, ADCC, and antitumor activity. Clin Cancer Res 2011; 17:1024-32.
93. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 1991; 51:144-9.
94. Frost JD, Hank JA, Reaman GH etal. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 1997; 80:317-33.
95. Kramer K, Humm JL, Souweidane MM etal. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol 2007; 25:5465-70.
96. Nakamura K, Tanaka Y, Shitara K, Hanai N. Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions. Cancer Immunol Immunother 2001; 50:275-84.
97. Kramer K, Gerald WL, Kushner BH, Larson SM, Hameed M, Cheung NK. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma. Clin Cancer Res 1998; 4:2135-9.
98. Yang RK, Sondel PM. Anti-GD2 Strategy in the Treatment of Neuroblastoma. Drugs Future 2010; 35:665-80.
99. Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest 2007; 25:67-77.
100. Cheresh DA, Honsik CJ, Staffileno LK, Jung G, Reisfeld RA. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Proc Natl Acad Sci USA 1985; 82:5155-9.
101. Chapman PB, Yuasa H, Houghton AN. Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside. J Immunol 1990; 145:891-8.
102. Kirkwood JM, Mascari RA, Edington HD etal. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer 2000; 88:2693-702.
103. Kaminski MJ, MacKenzie CR, Mooibroek MJ etal. The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular beta-sheet interaction between vh domains. J Biol Chem 1999; 274:5597-604.
104. Fernandes DM, Baird AM, Berg LJ, Rock KL. A monoclonal antibody reactive with a 40-kDa molecule on fetal thymocytes and tumor cells blocks proliferation and stimulates aggregation and apoptosis. J Immunol 1999; 163:1306-14.
105. Retter MW, Johnson JC, Peckham DW etal. Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts. Cancer Res 2005; 65:6425-34.
106. Carr A, Mullet A, Mazorra Z etal. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 2000; 19:241-7.
107. Carr A, Mesa C, Arango M, Vazquez AM, Fernandez LE. In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody. Hybrid Hybridomics 2002; 21:463-8.
108. Coberly SK, Chen FZ, Armanini MP etal. The RAV12 monoclonal antibody recognizes the N-linked glycotope RAAG12: expression in human normal and tumor tissues. Arch Pathol Lab Med 2009; 133:1403-12.
109. Li JC, Li R. RAV12 accelerates the desensitization of Akt/PKB pathway of insulin-like growth factor I receptor signaling in COLO205. Cancer Res 2007; 67:8856-64.
110. Burris HA III, Rosen LS, Rocha-Lima CM etal. Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma. Clin Cancer Res 2010; 16:1673-81.
111. Mazorra Z, Mesa C, Fernandez A, Fernandez L. Immunization with GM3 ganglioside nanoparticulated vaccine confers an effector CD8+ T cells-mediated protection against melanoma B16 challenge. Cancer Immunol Immunother 2008; 57:1771-80.
112. Hakomori S. The glycosynapse. Proc Natl Acad Sci USA 2002; 99:225-32.